Milestone Pharmaceuticals Inc

NASDAQ MIST

Data sourced from

and

Daily

Download Data

Milestone Pharmaceuticals Inc Price to Earnings Ratio (P/E) on June 03, 2024: -2.58

Milestone Pharmaceuticals Inc Price to Earnings Ratio (P/E) is -2.58 on June 03, 2024, a 7.32% change year over year. The price to earnings ratio (P/E ratio) compares the market price per share of a company's stock to its earnings per share (EPS). It is calculated by dividing the market capitalization by the net income, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's earnings. A higher P/E ratio indicates that investors are willing to pay a higher price for each unit of earnings, suggesting higher market expectations for future earnings growth.

Milestone Pharmaceuticals Inc 52-week high Price to Earnings Ratio (P/E) is -0.00 on March 14, 2024, which is 99.94% above the current Price to Earnings Ratio (P/E).
Milestone Pharmaceuticals Inc 52-week low Price to Earnings Ratio (P/E) is -2,412.77 on August 10, 2023, which is -93,274.61% below the current Price to Earnings Ratio (P/E).
Milestone Pharmaceuticals Inc average Price to Earnings Ratio (P/E) for the last 52 weeks is -20.95.

NASDAQ: MIST

Milestone Pharmaceuticals Inc

CEO	Mr. Joseph G. Oliveto M.B.A.
IPO Date	May 9, 2019
Location	Canada
Headquarters	1111 Dr. Frederik-Philips Boulevard, Montreal, QC, Canada, H4M 2X6
Employees	47
Sector	Healthcare
Industry	Biotechnology

Description

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Key trends